誉衡药业
(002437)
| 流通市值：65.92亿 | | | 总市值：70.09亿 |
| 流通股本：20.99亿 | | | 总股本：22.32亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,664,997,338.49 | 1,099,501,266.79 | 551,255,672.12 | 2,440,732,030.17 |
| 营业收入 | 1,664,997,338.49 | 1,099,501,266.79 | 551,255,672.12 | 2,440,732,030.17 |
| 二、营业总成本 | 1,463,760,914.56 | 977,868,310.54 | 493,551,043.76 | 2,218,794,751.25 |
| 营业成本 | 892,117,691.73 | 579,512,077.52 | 281,637,041.68 | 1,135,911,990.4 |
| 税金及附加 | 25,187,399.78 | 16,446,942.36 | 8,690,670.16 | 33,805,563.23 |
| 销售费用 | 411,395,500.83 | 294,238,047.8 | 158,753,641.89 | 792,647,941.82 |
| 管理费用 | 85,874,163 | 56,753,730.91 | 29,190,700.92 | 166,704,878.22 |
| 研发费用 | 49,714,579.12 | 30,316,235.75 | 15,046,259.26 | 90,792,091.72 |
| 财务费用 | -528,419.9 | 601,276.2 | 232,729.85 | -1,067,714.14 |
| 其中:利息费用 | 1,795,775.39 | 2,340,656.38 | 136,814.28 | 9,820,044.88 |
| 其中:利息收入 | 3,723,490.24 | 2,546,567.2 | 1,415,676.57 | 9,959,815.69 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 37,690,053.1 | 8,559,844.12 | 3,559,330.01 | -13,979,364.47 |
| 加:投资收益 | -565,419.78 | 175,170.34 | 186,760.17 | 5,250,989.35 |
| 资产处置收益 | 3,672,501.28 | 3,660,243.29 | 3,400,000 | 3,395,603.19 |
| 资产减值损失(新) | -930,377.77 | -906,206.2 | -263,230.63 | -4,866,432.46 |
| 信用减值损失(新) | 16,215.64 | -4,538.7 | 76,048.59 | 1,417,486.85 |
| 其他收益 | 24,134,568.42 | 18,755,923.47 | 4,406,097.57 | 71,697,423.25 |
| 四、营业利润 | 265,253,964.82 | 151,873,392.57 | 69,069,634.07 | 284,852,984.63 |
| 加:营业外收入 | 4,996,334.88 | 458,669.14 | 44,415.91 | 1,215,971.16 |
| 减:营业外支出 | 916,973.7 | 243,050.22 | 163,826.36 | 2,376,835.33 |
| 五、利润总额 | 269,333,326 | 152,089,011.49 | 68,950,223.62 | 283,692,120.46 |
| 减:所得税费用 | 21,409,752.07 | 14,664,998.51 | 7,018,639 | 41,152,085.53 |
| 六、净利润 | 247,923,573.93 | 137,424,012.98 | 61,931,584.62 | 242,540,034.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 247,923,573.93 | 137,424,012.98 | 61,931,584.62 | 242,540,034.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 243,763,036.93 | 134,422,001.01 | 60,252,267.26 | 232,759,457.12 |
| 少数股东损益 | 4,160,537 | 3,002,011.97 | 1,679,317.36 | 9,780,577.81 |
| 扣除非经常损益后的净利润 | 178,162,705.84 | 106,654,653.85 | 49,733,030.46 | 183,308,910.66 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.06 | 0.03 | 0.11 |
| (二)稀释每股收益 | 0.11 | 0.06 | 0.03 | 0.1 |
| 八、其他综合收益 | -639,692.29 | -159,250.63 | -40,526.17 | 476,998.7 |
| 归属于母公司股东的其他综合收益 | -639,692.29 | -159,250.63 | -40,526.17 | 476,998.7 |
| 九、综合收益总额 | 247,283,881.64 | 137,264,762.35 | 61,891,058.45 | 243,017,033.63 |
| 归属于母公司股东的综合收益总额 | 243,123,344.64 | 134,262,750.38 | 60,211,741.09 | 233,236,455.82 |
| 归属于少数股东的综合收益总额 | 4,160,537 | 3,002,011.97 | 1,679,317.36 | 9,780,577.81 |
| 公告日期 | 2025-10-29 | 2025-08-27 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |